Dr Clare Slaney is a Senior Research Fellow at the Peter MacCallum Cancer Centre, where she conducts translational cancer immunology research focused on developing next-generation immunotherapies for cancer. She works with a multidisciplinary team of postdoctoral researchers, PhD students, and research assistants to advance innovative therapeutic approaches.

Her research centres on understanding and manipulating immune–tumour interactions, with a focus on engineered T cell therapies and complementary immunotherapy platforms. These include chimeric antigen receptor (CAR) T cells, bispecific platforms, and mRNA-enabled immunomodulation. A key goal of her work is to overcome major challenges in cancer treatment, such as antigen heterogeneity, immune suppression, and limited T cell persistence.

Dr Slaney has published more than 50 peer-reviewed papers in prominent journals, including Nature Medicine, Cancer Research, Clinical Cancer Research, and Cancer Discovery. Her research program is supported by consistent competitive grant funding and is recognised for its innovation and translational impact.

In 2021, Dr Slaney co-founded the spinout company Currus Biologics, which has since completed a Series A investment and is advancing novel immunotherapy platforms toward clinical translation. This work reflects her commitment to translating fundamental discoveries into real-world therapeutic applications and fostering productive academic–industry collaborations.

Dr Slaney actively seeks academic, clinical, and industry partnerships to accelerate the development of innovative cancer immunotherapies. Prospective students and collaborators are encouraged to contact her directly to discuss potential opportunities.

Related pages

Currus Biologics